RxSight, Inc. 8-K

What Happened RxSight, Inc. (filed Form 8-K on December 22, 2025) announced that Shelley Thunen notified the company on December 16, 2025 that she will transition from her role as Chief Financial Officer and principal financial and accounting officer effective upon the earlier of the appointment of her successor or January 31, 2026. Ms. Thunen has agreed to provide transition support as a consultant after her separation date; the company expects to enter into a Transition Agreement and a Consulting Agreement effective as of her employment separation date. The company issued a press release about the pending transition on December 22, 2025 (Exhibit 99.1).

Key Details

• Transition timing: effective upon appointment of a successor or January 31, 2026, whichever is sooner.
• 2025 compensation: Ms. Thunen remains eligible for an annual cash bonus for fiscal 2025 (as determined by the Board) and will receive base salary through the transition date.
• Consulting terms: non‑refundable retainers of $15,000 for each of January, February and March 2026 (payable if the company terminates the consulting agreement without cause before March 31, 2026), plus an hourly consulting rate of $500. Consulting term scheduled to end December 31, 2026.
• Equity treatment: Ms. Thunen’s outstanding stock options will continue to vest under their original terms while she provides services under the Consulting Agreement.

Why It Matters This filing notifies investors of a CFO leadership change and the company’s steps to ensure continuity of financial leadership and knowledge transfer. The consulting arrangement, continued vesting of options, and eligibility for the 2025 bonus are retention and transition measures that may help maintain operational stability during the CFO handover. Investors should note the timing (successor appointment or Jan 31, 2026) and the consulting term through year‑end 2026 for ongoing access to Ms. Thunen’s financial expertise.